Maddalena Frau, Maria L. Tomasi, Maria M. Simile, Maria I. Demartis, Fabiana Salis, Gavinella Latte, Diego F. Calvisi, Maria A. Seddaiu, Lucia Daino, Claudio F. Feo, Stefania Brozzetti, Giuliana Solinas, Satoshi Yamashita, Toshikazu Ushijima, Francesco Feo, Rosa M. Pascale – 9 February 2012 – Down‐regulation of the liver‐specific MAT1A gene, encoding S‐adenosylmethionine (SAM) synthesizing isozymes MATI/III, and up‐regulation of widely expressed MAT2A, encoding MATII isozyme, known as MAT1A:MAT2A switch, occurs in hepatocellular carcinoma (HCC).

Robert Hayden Broomhead, Sanjiv Patel, Bimbi Fernando, James O'Beirne, Susan Mallett – 8 February 2012 – In the United Kingdom, liver transplantation using donation after circulatory determination of death (DCDD) organs has increased steadily over the last few years and now accounts for 20% of UK transplant activity. The procurement of DCDD livers is actively promoted as a means of increasing the donor pool and bridging the evolving disparity between the wait‐list length and the number of transplants performed.

Trina J. Hollatz, Alexandru Musat, Susanne Westphal, Catherine Decker, Anthony M. D'Alessandro, Jon Keevil, Li Zhanhai, James R. Runo – 8 February 2012 – Portopulmonary hypertension (PoPH) refers to pulmonary arterial hypertension associated with portal hypertension with or without evidence of an underlying liver disease. Despite the potential for curing PoPH with liver transplantation, the presence of moderate or severe PoPH is associated with increased morbidity and mortality and is, therefore, a contraindication to transplantation.

Marie A. Laryea, Kymberly D. Watt – 8 February 2012 – The reinfection of the hepatic allograft with hepatitis B virus and hepatitis C virus can have important sequelae that result in poor long‐term patient and graft survival. Although a response to treatment with antiviral medications can improve these outcomes, not all patients tolerate these medications or experience viral eradication. Avoiding reinfection of the graft is the most effective means of improving the long‐term outcomes for these patient populations.

P. Thomas Cherian, Nigel D. Heaton – 6 February 2012

Yan Zhao, Man Yang, Xingshun Qi, Guohong Han, Daiming Fan – 6 February 2012

Milan J. Sonneveld, Vincent Rijckborst, Stefan Zeuzem, E. Jenny Heathcote, Krzysztof Simon, Hakan Senturk, Suzan D. Pas, Bettina E. Hansen, Harry L.A. Janssen – 6 February 2012 – Peginterferon (PEG‐IFN) treatment of hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB) results in HBeAg loss in 30% of patients, but clearance of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) from serum is less often achieved.

Korosh Khalili, Morris Sherman – 6 February 2012

Salvatore Petta, Antonio Craxì – 6 February 2012

Masato Tsuchiya, Cheng Ji, Oksana Kosyk, Svitlana Shymonyak, Stepan Melnyk, Hiroshi Kono, Volodymyr Tryndyak, Levan Muskhelishvili, Igor P. Pogribny, Neil Kaplowitz, Ivan Rusyn – 6 February 2012 – Alcoholic liver injury is a major public health issue worldwide. Even though the major mechanisms of this disease have been established over the past decades, little is known about genetic susceptibility factors that may predispose individuals who abuse alcoholic beverages to liver damage and subsequent pathological conditions.